Last reviewed 2026-05-18 · How we verify

ET140203 T Cells

Eureka Therapeutics Inc. · Phase 1 active Small molecule Quality 25/100

ET140203 T Cells is a Cell Therapy Small molecule drug developed by Eureka Therapeutics Inc.. It is currently in Phase 1 development.

Engineered T cell therapy designed to target specific disease antigens, though the precise molecular target has not been publicly disclosed.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ET140203 T Cells
Sponsor	Eureka Therapeutics Inc.
Drug class	Cell Therapy
Modality	Small molecule
Phase	Phase 1

Mechanism of action

ET140203 T Cells appear to be an engineered T cell product, likely utilizing Eureka Therapeutics' proprietary T cell receptor or chimeric antigen receptor technology platforms. The specific antigen target and mechanism of T cell activation have not been publicly characterized.

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ET140203 T Cells CI brief — competitive landscape report
ET140203 T Cells updates RSS · CI watch RSS
Eureka Therapeutics Inc. portfolio CI

Frequently asked questions about ET140203 T Cells

What is ET140203 T Cells?

ET140203 T Cells is a Cell Therapy drug developed by Eureka Therapeutics Inc..

How does ET140203 T Cells work?

Engineered T cell therapy designed to target specific disease antigens, though the precise molecular target has not been publicly disclosed.

Who makes ET140203 T Cells?

ET140203 T Cells is developed by Eureka Therapeutics Inc. (see full Eureka Therapeutics Inc. pipeline at /company/eureka-therapeutics-inc).

What drug class is ET140203 T Cells in?

ET140203 T Cells belongs to the Cell Therapy class. See all Cell Therapy drugs at /class/cell-therapy.

What development phase is ET140203 T Cells in?

ET140203 T Cells is in Phase 1.

Drug class: All Cell Therapy drugs
Manufacturer: Eureka Therapeutics Inc. — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing